Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Anemia of Chronic Kidney Disease
Interventions
DRUG

Cholecalciferol

Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for \> 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Johns Hopkins University

OTHER

NCT01532349 - Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter